June 24, 2026
Onco-Innovations Limited
ISIN: CA68237C1059
Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010
Vancouver, Canada - June 23, 2026 - Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce that it has entered...
Read more >>Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program
Vancouver, Canada – April 28, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) announced, further to its news release dated April 21, 2026, the successful scale-up of key intermediates[i] A83 and B4, representing an advancement in the Company’s chemistry, manufacturing and...
Read more >Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies
Vancouver, Canada – April 23, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce that it has advanced an analytical method used to measure and control a key polymer within its PNKP Inhibitor Technology (the “Technology”), supporting continued...
Read more >Onco-Innovations Announces Completion of Analytical Method Development for Monomer Intermediate 1 Supporting ONC010 Program
Vancouver, Canada – April 21, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) announces the successful completion of a significant milestone with Dalton Pharma Services (“Dalton”), focused on analytical method development for purity determination of Intermediate 1 (monomer) of its proprietary...
Read more >Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy
Company also announces Marketing Engagement Vancouver, Canada – April 7, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce the execution of an engagement agreement with Research & Development Incentives Partners (“RDI Partners”), and the formation of Onco-Innovations AU...
Read more >Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Vancouver, Canada – February 4, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) announces that it has filed a preliminary base shelf prospectus dated February 3, 2026 (the “Base Shelf Prospectus”) with the securities regulatory authorities in each of the provinces...
Read more >Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering
Vancouver, Canada – December 07, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) (“Onco” or the “Company”) is pleased to announce that it has engaged a U.S. investment bank to serve as its capital markets advisor in connection with the Company’s intention to pursue a...
Read more >Onco-Innovations Attends University of Alberta’s 2025 Innovation Awards
Vancouver, Canada – November 25, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (Frankfurt: W1H, WKN: A3EKSZ)(OTCQB: ONNVF) ("Onco" or the "Company") is pleased to announce that it was invited to attend the University of Alberta’s 2025 Innovation Awards in Edmonton, Alberta, which were held on November 21, 2025. The annual...
Read more >Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical Studies
Vancouver, Canada – November 20, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce that its manufacturing partner, Dalton Pharma Services (“Dalton”), has initiated process optimization and intermediate scale-up activities for A83B4C63, the Company’s proprietary PNKP Inhibitor Technology....
Read more >Onco-Innovations Advances AI and Quantum Drug Discovery with Kuano Collaboration to Accelerate PNKP Inhibitor Technology Development
Vancouver, Canada – November 18, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce that it is initiating a pilot project with Kuano Ltd. (Kuano) to accelerate development of Onco’s PNKP Inhibitor Technology (also known as A83B4C63). This...
Read more >